The global biopharmaceutical industry is increasingly turning to specialized manufacturing partners to improve scalability, control costs, and accelerate product development. This shift is creating new opportunities for microbial contract development and manufacturing organizations (CDMOs).
According to the latest industry analysis, the global microbial CDMO market was valued at USD 3.96 billion in 2025 and is projected to reach approximately USD 9.15 billion by 2035, growing at a CAGR of 8.74% between 2026 and 2035. The market is expected to reach around USD 4.3 billion in 2026.
Microbial CDMOs support pharmaceutical and biotechnology companies with development, process optimization, fermentation, scale-up, and manufacturing of products such as recombinant proteins, vaccines, enzymes, plasmid DNA, and other microbial-derived biopharmaceuticals. Growing biologics pipelines, limited in-house manufacturing capacity, and increasing regulatory requirements are encouraging companies to outsource these activities.
Key Market Trends
Recombinant proteins accounted for the largest share by molecule type in 2025, representing approximately 45% of the market. Meanwhile, plasmid DNA is projected to record the fastest growth, supported by increasing applications in gene therapy, cell therapy, and vaccine development.
By expression system, bacterial systems dominated with around 68% share, benefiting from rapid growth, established manufacturing processes, and cost-efficient production. Engineered yeast is expected to grow rapidly as demand increases for advanced biologics and complex proteins.
The antibiotics and vaccines segment led applications with approximately 41% share, while gene therapy and mRNA feedstock applications are emerging as high-growth areas. Among end users, big pharmaceutical companies represented about 54% of the market, while biotech startups are expected to experience the fastest growth as emerging companies increasingly outsource manufacturing.
AI and Advanced Biomanufacturing
Artificial intelligence is becoming an important enabler for microbial CDMOs. AI-driven analytics can help optimize microbial strains, fermentation conditions, process parameters, production yields, and quality-control workflows.
Combined with high-cell-density fermentation, automation, advanced analytics, and continuous manufacturing, these technologies are helping CDMOs improve efficiency while shortening development timelines.
Regional Outlook
North America held the leading position in 2025, accounting for approximately 41.5% of the global market. Its established biopharmaceutical ecosystem, strong R&D investment, advanced manufacturing infrastructure, and widespread outsourcing culture continue to support regional leadership.
Asia Pacific is expected to register the fastest growth during the forecast period. Increasing biotechnology investment, expanding manufacturing capacity, cost-efficient production capabilities, and government support in countries such as China and India are attracting international biopharma partnerships.
Competitive Landscape
Key companies operating in the microbial CDMO space include Lonza Group AG, Fujifilm Diosynth Biotechnologies, AGC Biologics, Thermo Fisher Scientific, Boehringer Ingelheim, and WuXi Biologics.
Recent investments, facility expansions, technology development, and strategic partnerships indicate that CDMOs are positioning themselves to support increasingly complex biologics and advanced therapeutic pipelines.
Looking Ahead
The microbial CDMO industry is moving beyond traditional contract manufacturing toward integrated development, process optimization, advanced fermentation, and scalable GMP production. As pharmaceutical companies prioritize speed, flexibility, and capital efficiency, specialized CDMOs are likely to become increasingly important throughout the biologics development lifecycle.
Key figures at a glance:
- 2025 Market Size: USD 3.96 Billion
- 2026 Market Size: USD 4.3 Billion
- 2035 Forecast: USD 9.15 Billion
- CAGR: 8.74% (2026–2035)
- Leading Region: North America
- Fastest-Growing Region: Asia Pacific
Download Customized Sample: https://www.towardshealthcare.com/download-sample/6686
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium